Nanobody- and mini-G protein-enabled molecular pharmacology of HCAR1

点击翻译按钮获取中文摘要

Project Summary/Abstract Separate from its roles in cellular energy metabolism, the metabolite lactate influences multiple physiological processes and contributes to cancer progression by acting as a signaling molecule. Cancer cells often undergo metabolic reprogramming which results in increased lactate production and secretion. Extracellular lactate activates hydroxycarboxylic acid receptor 1 (HCAR1), an understudied G protein-coupled receptor that promotes tumor growth by driving cancer cell proliferation, stimulating tumor vascularization, and inhibiting immune surveillance. Inhibiting HCAR1 activity represents a promising strategy for cancer treatment, but the lack of selective pharmacological tools targeting HCAR1 hampers our ability to target this receptor in disease and limits our understanding of HCAR1 function in physiology. Our long-term goal is to understand the molecular basis for ligand recognition by HCAR1 and to use this information to design selective small molecules targeting this receptor. This project will lay the foundation for future structure-based drug discovery efforts by determining the ability of known HCAR1 ligands to promote binding between purified HCAR1 and engineered G proteins (mini-G proteins) or camelid single-chain antibody fragments (nanobodies). In Aim 1, we will examine the allosteric coupling between currently available HCAR1 agonists and a panel of mini-G proteins and investigate the mechanism of action of potential HCAR1 antagonists. In Aim 2, we will identify conformationally selective nanobodies that recognize HCAR1 and determine their selectivity and binding mode at HCAR1. In both aims, we will determine conditions to form stable HCAR1 complexes for future structural studies of HCAR1 in multiple states. This work will provide insight into the molecular pharmacology of currently available HCAR1 ligands, discover novel nanobodies to probe HCAR1 function, and enable future structure-based design of HCAR1 ligands for cancer treatment.